Access cutting-edge metastatic melanoma treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Access metastatic melanoma specialists in Chicago at no cost
This study follows strict safety protocols and ethical guidelines
All study-related metastatic melanoma treatment provided free
This phase I/II trial investigates the best dose, possible benefits and/or side effects of tazemetostat in combination with dabrafenib and trametinib in treating patients with melanoma that has a specific mutation in the BRAF gene (BRAFV600) and that has spread from where it first started (primary site) to other places in the body (metastatic). Tazemetostat, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving tazemetostat i
Sponsor: National Cancer Institute (NCI)
Check if you qualify for this metastatic melanoma clinical trial in Chicago, IL
If you're searching for metastatic melanoma treatment options in Chicago, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced metastatic melanoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.